Skip to content
Courts & Crime 90.5% of intimate feminicide victims in Puerto Rico did not seek protectionWeather San Juan …Water San Juan Bay …Tropics No stormsNext holiday Discovery of Puerto Rico Day · Nov 19 · Hurricane season Day 171 of 183Culture Victorino Stylo asks for prayers before intestinal surgeryCulture Josué Comedy to star in family Christmas film 'Lord, Have Mercy'Courts & Crime Woman arrested, two minors detained after rifle and drugs seized in AreciboCourts & Crime 90.5% of intimate feminicide victims in Puerto Rico did not seek protectionWeather San Juan …Water San Juan Bay …Tropics No stormsNext holiday Discovery of Puerto Rico Day · Nov 19 · Hurricane season Day 171 of 183Culture Victorino Stylo asks for prayers before intestinal surgeryCulture Josué Comedy to star in family Christmas film 'Lord, Have Mercy'Courts & Crime Woman arrested, two minors detained after rifle and drugs seized in Arecibo
EA
hematologist-oncologist

Edith A. Perez

Known for: Chief medical officer at Cornerstone Specialty Network · Led development of GAZYVA, PERJETA, ALECENSA, TECENTRIQ · Co-founded National Marathon to Finish Breast Cancer · N9831 trial contributor on trastuzumab.

Edith A. Perez: biography

Early life and education

Edith A. Perez was born in Humacao, Puerto Rico. She graduated magna cum laude with a B.S. in biology from the University of Puerto Rico and earned her medical degree at the University of Puerto Rico School of Medicine in San Juan. Perez completed her residency in internal medicine at Loma Linda University Medical Center in California. She served two years in the National Health Service Corps, then finished a fellowship in hematology and oncology at the UC Davis School of Medicine. She later completed executive education programs at the Harvard Kennedy School and the Wharton School of the University of Pennsylvania. Perez holds board certifications in internal medicine, medical oncology and hematology. 1

Academic and clinical career at Mayo Clinic

Perez held positions at Mayo Clinic that included teaching, research, patient care and work on breast cancer treatment as well as translational biomarkers. She received a Mayo-endowed professorship and served as deputy director at large for the Mayo Clinic Cancer Center. Her work included participation in the N9831 trial. That study showed that adding trastuzumab to chemotherapy improved disease-free survival and overall survival for patients with early-stage HER-2 positive breast cancer. The combination improved survival rates by 33 percent compared with chemotherapy alone. Global collaborations and funding from the National Cancer Institute, the National Institutes of Health and foundations such as the Breast Cancer Research Foundation supported her research during this period. She is now Professor Emeritus at Mayo Clinic. 1

Industry leadership roles

Perez served as vice president of the BioOncology Medical Unit at Genentech from 2015 to 2018 and as a member of the Oncology Commercial Leadership Team. In those roles she contributed to the development and launch of several oncology therapeutics including GAZYVA, PERJETA, ALECENSA and TECENTRIQ. She also sat on the Genentech/Roche Cancer Immunotherapy Governance Committee. From 2020 to 2024 she was chief medical officer at Bolt Biotherapeutics, where she directed development of an immune-oncology pipeline. She currently serves on scientific advisory committees for two early-stage biotechnology companies. 1

Board service, advocacy and major works

Perez serves on the board of directors of the Food Allergy Research Foundation and the Puerto Rico Science, Technology & Research Trust. She has been a member of multiple National Cancer Institute committees including the Board of Scientific Advisors and the Clinical Trials and Translational Committee. She has participated in five National Academies of Sciences, Engineering, and Medicine consensus groups. These include work on the 2021-2023 report Improving Diversity Across the Clinical Trial and Research Ecosystem and the 2024-2025 report Aligning Investments in Therapeutic Development with Disease Burden and Unmet Needs. Perez served on the board of Artiva Biotherapeutics from 2022 to 2024. She has contributed to diversity leadership and philanthropic efforts with the American Society of Clinical Oncology, the American Association for Cancer Research, The DONNA Foundation, Stand Up to Cancer and the Komen Foundation. She co-founded the National Marathon to Finish Breast Cancer. The organization raises funds for underserved women and for genomics and immunologic translational cancer research. Perez participates in the marathon each year. Proceeds from the marathon have assisted more than 20,000 families and raised over 3.3 million dollars for cancer research. The group also runs events and programs focused on survivorship, education and awareness. 1

Ties to Puerto Rico

Nacida en Humacao, Perez obtuvo sus grados de bachillerato y médico en instituciones de la Universidad de Puerto Rico. Mantiene una conexión con la isla a través de su servicio en la junta del Puerto Rico Science, Technology & Research Trust. 1

Questions about Edith A. Perez

Where is Edith A. Perez from?

Edith A. Perez was born in Humacao, Puerto Rico.

What role did Edith A. Perez play in the N9831 trial?

She contributed to the trial that showed adding trastuzumab to chemotherapy improved survival rates by 33 percent for early-stage HER-2 positive breast cancer patients.

Which oncology drugs did Perez help develop and launch at Genentech?

She contributed to GAZYVA, PERJETA, ALECENSA and TECENTRIQ while serving as vice president of the BioOncology Medical Unit.

What organization did Perez co-found to support breast cancer patients?

She co-founded the National Marathon to Finish Breast Cancer, which has assisted over 20,000 families and raised more than 3.3 million dollars for research.

Sources

  1. Wikipedia: Edith A. Perez
  2. Wikidata: Q18389345
  3. National Institutes of Health (cited by Wikipedia)
  4. Universidad de Puerto Rico (cited by Wikipedia)
  5. Harvard University (cited by Wikipedia)
  6. DOI (cited by Wikipedia)

We did not find a freely licensed photo we could use, so we show initials instead.

Reviewed November 18, 2026. Original biography by PuertoRico.com. Editorial policy